<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1679-4974</journal-id>
<journal-title><![CDATA[Epidemiologia e Serviços de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Epidemiol. Serv. Saúde]]></abbrev-journal-title>
<issn>1679-4974</issn>
<publisher>
<publisher-name><![CDATA[Secretaria de Vigilância em Saúde e Ambiente - Ministério da Saúde do Brasil]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1679-49742020000100020</article-id>
<article-id pub-id-type="doi">10.5123/s1679-49742020000100017</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Fatores associados à gravidade dos eventos adversos pós-vacinação contra a febre amarela durante o maior surto da doença registrado no Brasil, 2016-2017]]></article-title>
<article-title xml:lang="es"><![CDATA[Factores asociados a la gravedad de los eventos adversos posvacunación contra la fiebre amarilla durante el mayor brote de la enfermedad registrado en Brasil, 2016-2017]]></article-title>
<article-title xml:lang="en"><![CDATA[Factors associated with severity of adverse events following yellow fever vaccination during the biggest outbreak of the disease recorded in Brazil, 2016-2017]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lucena]]></surname>
<given-names><![CDATA[Adriana Regina Farias Pontes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[Líbia Roberta de Oliveira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Percio]]></surname>
<given-names><![CDATA[Jadher]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[Sandra Maria Deotti]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romano]]></surname>
<given-names><![CDATA[Alessandro Pecego Martins]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domingues]]></surname>
<given-names><![CDATA[Carla Magda Allan Santos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Ministério da Saúde Secretaria de Vigilância em Saúde ]]></institution>
<addr-line><![CDATA[Brasília DF]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>29</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S1679-49742020000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S1679-49742020000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S1679-49742020000100020&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo:  analisar características, incidência e fatores associados aos eventos adversos graves (EAGs) pós-vacinação contra febre amarela durante surto da doença no Brasil (2016-2017).  Métodos:  estudo de caso-controle, com dados do Sistema de Informações do Programa Nacional de Imunizações (SI-PNI); foram considerados casos os EAGs, e controles os eventos adversos não graves (EANGs).  Resultados:  foram analisados 135 casos de EAG e 1.058 controles; dos 135 EAGs, 79 (58,5%) eram homens, e a mediana de idade dos casos, 28 anos (intervalo interquartílico: 9-49); a incidência de EAG em janeiro de 2017 chegou a 1,3 caso por 100 mil doses aplicadas; houve associação estatística com o sexo masculino (odds ratio [OR]=1,73; IC95% 1,20;2,48), ser primovacinado (OR=1,65; IC95% 1,01;2,71), e ter idade &#8805;60 anos, tomando-se por referência os menores de 5 anos (OR=4,4; p-valor &lt;0,02).  Conclusão:  EAG pela vacina da febre amarela apresentou maior chance de ocorrer em homens, idosos e primovacinados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  analizar características, incidencia y factores asociados a eventos adversos graves (EAG) posvacunación contra la fiebre amarilla durante brote de la enfermedad en Brasil (2016-2017).  Métodos:  estudio de caso-control, con datos del Sistema de Informaciones del Programa Nacional de Inmunizaciones (SI-PNI); se consideraron casos los EAG, y controles los eventos adversos no graves (EANG).  Resultados:  se analizaron 135 casos de EAG y 1.058 controles; de los 135 EAG, 79 (58,5%) eran hombres, con edad promedio de 28 años [rango intercuartílico: 9-49]; la incidência en enero de 2017 llegó a 1,3 caso por 100 mil dosis aplicadas; ocurrió asociación estadística con el sexo masculino (odds ratio [OR]=1,73 - IC95% 1,20;2,48), ser primovacunado (OR=1,65 - IC95% 1,01;2,71), y tener &#8805;60 años de edad tomando como referencia a los menores de 5 años (OR=4,4; p-valor &lt;0,02).  Conclusión:  EAG por la vacuna de la fiebre amarilla presentó mayor probabilidad de ocurrir en hombres, ancianos y primovacunados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  to analyze characteristics, incidence and factors associated with serious adverse events (SAEs) following yellow fever vaccination during an outbreak of the disease in Brazil (2016-2017).  Methods:  this was a case-control study using data from the National Immunization Program Information System (SI-PNI); SAE were considered to be cases, and non-serious adverse events (NSAE) were considered to be controls.  Results:  we analyzed 135 SAE cases and 1,058 controls; of the 135 SAE, 79 (58.5%) were males and median age was 28 years [09-49]; incidence in January 2017 reached 1.3 case per 100,000 vaccine doses administered; there was statistical association with males (Odds Ratio [OR]=1.73 - 95%CI 1.20;2.48), primary vaccination (OR=1.65 - 95%CI 1.01;2.71), and being 60 years of age or older taking as reference those aged under 5 (OR=4.4; p-value &lt;0.02).  Conclusion:  SAE owing to yellow fever vaccine showed a greater chance of occurring in men, the elderly and primary vaccination.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Vacinas]]></kwd>
<kwd lng="pt"><![CDATA[Febre Amarela]]></kwd>
<kwd lng="pt"><![CDATA[Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Imunização]]></kwd>
<kwd lng="pt"><![CDATA[Estudos de Casos e Controles]]></kwd>
<kwd lng="es"><![CDATA[Vacunas]]></kwd>
<kwd lng="es"><![CDATA[Fiebre Amarilla]]></kwd>
<kwd lng="es"><![CDATA[Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Inmunización]]></kwd>
<kwd lng="es"><![CDATA[Estudios de Casos y Controles]]></kwd>
<kwd lng="en"><![CDATA[Vaccines]]></kwd>
<kwd lng="en"><![CDATA[Yellow Fever]]></kwd>
<kwd lng="en"><![CDATA[Drug-Related Side Effects and Adverse Reactions]]></kwd>
<kwd lng="en"><![CDATA[Immunization]]></kwd>
<kwd lng="en"><![CDATA[Case-Control Studies]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasconcelos]]></surname>
<given-names><![CDATA[PFC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Febre amarela]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>2003</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>275-93</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasconcelos]]></surname>
<given-names><![CDATA[PFC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Febre amarela: reflexões sobre a doença]]></article-title>
<source><![CDATA[Rev Bras Epidemiol]]></source>
<year>2002</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>244-58</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tauil]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos críticos do controle da febre amarela no Brasil]]></article-title>
<source><![CDATA[Rev Saúde Pública]]></source>
<year>2010</year>
<volume>44</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>555-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavalcante]]></surname>
<given-names><![CDATA[KRLJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tauil]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risco de reintrodução da febre amarela urbana no Brasil]]></article-title>
<source><![CDATA[Epidemiol Serv Saúde]]></source>
<year>2017</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>617-20</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Atenção à Saúde</collab>
<source><![CDATA[Febre amarela: guia para profissionais de saúde]]></source>
<year>2017</year>
<page-range>67</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnett]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Yellow fever: epidemiology and prevention]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2007</year>
<volume>44</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>850-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde</collab>
<article-title xml:lang=""><![CDATA[Vigila&#770;ncia epidemiolo&#769;gica da febre amarela e a importa&#770;ncia do monitoramento no peri&#769;odo sazonal, Brasil, 2014-2015]]></article-title>
<source><![CDATA[Bol Epidemiol]]></source>
<year>2015</year>
<volume>46</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde</collab>
<source><![CDATA[Situação epidemiológica da febre amarela no Brasil]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde</collab>
<article-title xml:lang=""><![CDATA[Emerge&#770;ncia epidemiolo&#769;gica de febre amarela no Brasil, no peri&#769;odo de dezembro de 2016 a julho de 2017]]></article-title>
<source><![CDATA[Bol Epidemiol]]></source>
<year>2017</year>
<volume>48</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde</collab>
<source><![CDATA[Nota informativa nº 94, de 2017/CGPNI/DEVIT/SVS/MST. Orientações e indicação de dose única da vacina febre amarela]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[LDC]]></given-names>
</name>
<name>
<surname><![CDATA[Barata]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surtos de febre amarela no estado de São Paulo, 2000-2010]]></article-title>
<source><![CDATA[Epidemiol Serv Saúde]]></source>
<year>2016</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>531-40</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde</collab>
<source><![CDATA[Manual de vigilância epidemiológica de eventos adversos pós-vacinação]]></source>
<year>2014</year>
<edition>3</edition>
<page-range>250</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Global manual on surveillance of adverse events following immunization]]></source>
<year>2014</year>
<page-range>109</page-range><publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Centro de Operações de Emergências em Saúde Pública sobre Febre Amarela</collab>
<source><![CDATA[Informe 34, 2017: monitoramento dos casos e o&#769;bitos de febre amarela no Brasil]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Breugelmans]]></surname>
<given-names><![CDATA[JG1]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Agbenu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Veit]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Domingo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010]]></article-title>
<source><![CDATA[Vaccine [Internet].]]></source>
<year>2013</year>
<volume>31</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1819-29</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanizaki]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ujiie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hori]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kanagawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kutsuna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Takeshita]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period]]></article-title>
<source><![CDATA[J Travel Med]]></source>
<year>2016</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>pii: taw012</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khromava]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Eidex]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Weld]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Kohl]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Bradshaw]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2005</year>
<volume>23</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>3256-63</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindsey]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Rabe]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Staples]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse event reports following yellow fever vaccination, 2007-13]]></article-title>
<source><![CDATA[J Travel Med]]></source>
<year>2016</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzetti]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Spragins]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review]]></article-title>
<source><![CDATA[Am J Trop Med Hyg]]></source>
<year>2012</year>
<volume>86</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>359-72</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monath]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of the risks and benefits of yellow fever vaccination including some new analyses]]></article-title>
<source><![CDATA[Expert Rev Vaccines]]></source>
<year>2012</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>427-88</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[MLF]]></given-names>
</name>
<name>
<surname><![CDATA[Homma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serious adverse events associated with yellow fever vaccine]]></article-title>
<source><![CDATA[Hum Vaccin Immunother]]></source>
<year>2015</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2183-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
